Results 111 to 120 of about 379,600 (302)

Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP [PDF]

, 1999
Raf-1 phosphorylates and activates MEK-1, a kinase that activates the extracellular signal regulated kinases (ERK). This kinase cascade controls the proliferation and differentiation of different cell types.
A Minden, A Sewing, AD Catling, B Hallberg, CJ Marshall, D Woods, DK Grandy, DK Morrison, DW Rose, F Schoentgen, Ferrell, J. E. Jr, Ferrell, J. E. Jr, H Mischak, HJ Schaeffer, JT Bruder, KL Guan, M Kortenjann, OV Gjorup, RM Lavbinsky, RM Tombes, S Häfner, S Li, SA Moodie, UR Rapp, W Kolch, W Kolch   +25 more
core   +1 more source

Accuracy of diagnostic codes and algorithms used to identify rheumatoid arthritis and juvenile idiopathic arthritis in administrative claims and electronic health records: systematic review and meta‐analysis.

Arthritis Care &Research, Accepted Article.
Objective This systematic review aimed to assess the diagnostic accuracy of algorithms used to identify rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) in electronic health records (EHRs). Methods We searched MEDLINE, Embase, and CENTRAL databases and included studies that validated case definitions against a reference standard such ...
Constanza Saka‐Herrán, Jessica Bennett, Yara Alkabti, Muhammad Fatir, Barbara Clyne, Caroline McCarthy, Gráinne Tynan, Nikki Dunne, Michelle Flood, Eoghan McCarthy, Frank Moriarty   +10 more
wiley   +1 more source

Membrane Fusion and SNAREs: Interaction with Ras Proteins. [PDF]

Int J Mol Sci, 2022
Margiotta A.
europepmc   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

Regulator of G-protein signaling 14 (RGS14) is a selective H-Ras effector.

PLoS ONE, 2009
BackgroundRegulator of G-protein signaling (RGS) proteins have been well-described as accelerators of Galpha-mediated GTP hydrolysis ("GTPase-accelerating proteins" or GAPs).
Francis S Willard, Melinda D Willard, Adam J Kimple, Meera Soundararajan, Emily A Oestreich, Xiaoyan Li, Nathaniel A Sowa, Randall J Kimple, Declan A Doyle, Channing J Der, Mark J Zylka, William D Snider, David P Siderovski   +12 more
doaj   +1 more source

Post-translational modification of RAS proteins. [PDF]

Curr Opin Struct Biol, 2021
Campbell SL, Philips MR.
europepmc   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source

Data from A Novel Senescence-Evasion Mechanism Involving Grap2 and Cyclin D Interacting Protein Inactivation by Ras Associated with Diabetes in Cancer Cells under Doxorubicin Treatment

, 2023
In‐Kyoung Lee, Seon-Yong Yeom, Sook-Ja Lee, Won Ki Kang, Chaehwa Park   +4 more
openalex   +2 more sources

Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation. [PDF]

Cancer Discov, 2022
Chen S, Vedula RS, Cuevas-Navarro A, Lu B, Hogg SJ, Wang E, Benbarche S, Knorr K, Kim WJ, Stanley RF, Cho H, Erickson C, Singer M, Cui D, Tittley S, Durham BH, Pavletich TS, Fiala E, Walsh MF, Inoue D, Monette S, Taylor J, Rosen N, McCormick F, Lindsley RC, Castel P, Abdel-Wahab O.   +26 more
europepmc   +1 more source

Cell-cycle–dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling [PDF]

, 2001
Michael Morgan, Oliver Dolp, Christoph Reuter   +2 more
openalex   +1 more source